These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32143347)

  • 21. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
    Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
    Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
    PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of 5-Hydroxy-3',4',7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance.
    Tsunekawa R; Katayama K; Hanaya K; Higashibayashi S; Sugimoto Y; Sugai T
    Chembiochem; 2019 Jan; 20(2):210-220. PubMed ID: 30187992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells.
    Takara K; Matsubara M; Yamamoto K; Minegaki T; Takegami S; Takahashi M; Yokoyama T; Okumura K
    Mol Med Rep; 2012 Mar; 5(3):603-9. PubMed ID: 22200670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
    Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
    Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
    Nakanishi T; Ross DD
    Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.
    Martín V; Sanchez-Sanchez AM; Herrera F; Gomez-Manzano C; Fueyo J; Alvarez-Vega MA; Antolín I; Rodriguez C
    Br J Cancer; 2013 May; 108(10):2005-12. PubMed ID: 23632480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
    Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
    BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
    Moinul M; Amin SA; Jha T; Gayen S
    Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
    Yang D; Kathawala RJ; Chufan EE; Patel A; Ambudkar SV; Chen ZS; Chen X
    Future Oncol; 2014 Aug; 10(11):1827-41. PubMed ID: 24295377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.